Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:56:18 EDT Fri 20 Sep 2024
Enter Symbol
or Name
USA
CA



News for U:REGN from 2023-09-21 to 2024-09-20 - 83 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-09-20 07:45U:REGNNews ReleaseDupixent(TM) (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
2024-09-13 12:15U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
2024-09-11 07:01U:REGNNews ReleaseEYLEA HD(TM) (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
2024-09-11 01:04U:REGNNews ReleaseDupixent(TM) (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
2024-09-11 00:59U:REGNNews ReleaseDupixent(TM) (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
2024-09-09 17:00U:REGNNews ReleaseLibtayo(TM) (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
2024-09-09 07:00U:REGNNews ReleaseRegeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
2024-08-26 07:00U:REGNNews ReleaseOrdspono(TM) (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
2024-08-26 01:00U:REGNNews ReleaseLatest Dupixent(TM) (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
2024-08-20 18:45U:REGNNews ReleaseRegeneron Provides Update on Biologics License Application for Linvoseltamab
2024-08-07 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations and Oncology Investor Webcast
2024-08-01 06:30U:REGNNews ReleaseRegeneron Reports Second Quarter 2024 Financial and Operating Results
2024-07-31 07:30U:REGNNews ReleaseRegeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
2024-07-03 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD
2024-06-28 07:00U:REGNNews ReleaseOdronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
2024-06-27 16:05U:REGNNews ReleaseRegeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024
2024-06-26 17:30U:REGNNews ReleaseDupixent(TM) (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
2024-06-16 06:10U:REGNNews ReleaseUpdated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma
2024-06-11 07:00U:REGNNews ReleaseKevzara(TM) (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic Arthritis (pJIA)
2024-05-31 01:05U:REGNNews ReleaseDupixent(TM) (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
2024-05-31 01:00U:REGNNews ReleaseUpdate on FDA Priority Review of Dupixent(TM) (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation
2024-05-29 07:15U:REGNNews ReleaseBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
2024-05-23 17:03U:REGNNews ReleasePromising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo(TM) (cemiplimab) to be Reported at ASCO
2024-05-20 14:15U:REGNNews ReleaseDupixent(TM) (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine
2024-05-17 13:46U:REGNNews ReleaseMore than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
2024-05-13 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)
2024-05-08 06:01U:REGNNews ReleaseLatest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks
2024-05-06 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2024-05-02 06:30U:REGNNews ReleaseRegeneron Reports First Quarter 2024 Financial and Operating Results
2024-04-29 07:00U:REGNNews ReleaseEYLEA(TM) HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases
2024-04-25 07:00U:REGNNews ReleaseRegeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases
2024-04-24 10:05U:REGNNews ReleaseRegeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
2024-04-22 17:54U:REGNNews ReleaseRegeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
2024-04-07 16:00U:REGNNews ReleaseLinvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma
2024-04-01 16:05U:REGNNews ReleaseRegeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024
2024-03-25 07:00U:REGNNews ReleaseRegeneron Provides Update on Biologics License Application for Odronextamab
2024-03-12 23:55U:REGNNews ReleaseHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
2024-03-12 21:30U:REGNNews ReleaseHigh School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization
2024-03-11 07:00U:REGNNews ReleasePraluent(TM) (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol
2024-03-08 07:00U:REGNNews ReleaseEYLEA(TM) HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
2024-02-23 01:00U:REGNNews ReleaseDupixent(TM) (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
2024-02-21 07:00U:REGNNews ReleaseLinvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review
2024-02-16 00:59U:REGNNews ReleaseJapan First in the World to Approve Dupixent ‚ ® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
2024-02-06 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2024-02-02 06:30U:REGNNews ReleaseRegeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
2024-02-02 06:00U:REGNNews ReleaseLinvoseltamab Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma
2024-01-30 07:01U:REGNNews ReleaseRegeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs
2024-01-25 14:29U:REGNNews ReleaseDupixent ‚ ® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
2024-01-24 12:05U:REGNNews ReleaseTop 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
2024-01-24 12:00U:REGNNews ReleaseTop 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards
2024-01-16 07:00U:REGNNews ReleaseDupixent ‚ ® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
2024-01-08 07:30U:REGNNews ReleaseMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo ® (cemiplimab) in Multiple Countries
2024-01-08 07:30U:REGNNews ReleaseMedison Pharma Announces Agreement with Regeneron Pharmaceuticals to Commercialize Libtayo ‚ ® (cemiplimab) in Multiple Countries
2024-01-05 16:05U:REGNNews ReleaseRegeneron to Report Fourth Quarter and Full Year 2023 Financial and Operating Results and Host Conference Call and Webcast on February 2, 2024
2023-12-18 16:05U:REGNNews ReleaseRegeneron Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-11 07:30U:REGNNews ReleaseRegeneron Named on Dow Jones Sustainability World Index for Fifth Consecutive Year
2023-12-10 19:30U:REGNNews ReleaseLatest Odronextamab Data in Relapsed/Refractory Follicular Lymphoma Showed Compelling Responses and Overall Maintenance of Patient-Reported Outcomes
2023-12-10 12:30U:REGNNews ReleaseUpdated Odronextamab Data from Relapsed/Refractory Diffuse Large B-cell Lymphoma Pivotal Trial Showed Deep and Durable Responses and the Potential of ctDNA To Predict Long-term Outcomes
2023-12-07 07:01U:REGNNews ReleaseUpdated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma
2023-12-07 02:31U:REGNNews ReleaseRegeneron to Share Progress of Novel Combination Therapies in Oncology at ESMO IO
2023-11-30 16:05U:REGNNews ReleaseRegeneron to Host Investor Call and Webcast on December 14, 2023 to Provide Updates Across Its Hematology Portfolio
2023-11-27 01:30U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
2023-11-15 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentation
2023-11-13 09:00U:REGNNews ReleaseRegeneron Commits $34 Million Over Five Years to Continue to Sponsor the Regeneron International Science and Engineering Fair (ISEF)
2023-11-03 07:00U:REGNNews ReleaseRegeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
2023-11-02 06:30U:REGNNews ReleaseRegeneron Reports Third Quarter 2023 Financial and Operating Results
2023-11-01 16:00U:REGNNews ReleaseEYLEA ‚ ® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
2023-10-26 16:00U:REGNNews ReleaseRegeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
2023-10-25 16:05U:REGNNews ReleaseRegeneron Announces Investor Conference Presentations
2023-10-22 14:59U:REGNNews ReleaseDupixent ‚ ® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
2023-10-21 08:48U:REGNNews ReleaseLibtayo ‚ ® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
2023-10-20 17:01U:REGNNews ReleaseRegeneron and Sanofi Provide Update on Dupixent ‚ ® (dupilumab) sBLA for Chronic Spontaneous Urticaria
2023-10-18 09:30U:REGNNews ReleaseRegeneron builds on Together for CHANGE ¢ „ ¢ initiative with five-year, ‚  $5 million commitment to fuel the STEM talent pipeline in Nashville, TN
2023-10-18 09:00U:REGNNews ReleaseTogether for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry
2023-10-15 18:05U:REGNNews ReleaseRegeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO
2023-10-05 09:43U:REGNNews ReleaseEYLEA ‚ ® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA
2023-10-03 07:00U:REGNNews ReleaseRegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
2023-10-03 07:00U:REGNNews ReleaseRegeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases
2023-09-29 08:30U:REGNNews ReleaseOdronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma (FL) and Diffuse Large B-cell Lymphoma (DLBCL) Accepted for FDA Priority Review
2023-09-28 16:05U:REGNNews ReleaseRegeneron to Report Third Quarter 2023 Financial and ‚  Operating Results and Host Conference Call and Webcast ‚  on November 2, 2023
2023-09-26 01:29U:REGNNews ReleaseDupixent ‚ ® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
2023-09-25 17:13U:REGNNews ReleaseUltragenyx Launches Evkeeza ‚ ® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH)
2023-09-25 08:35U:REGNNews ReleaseRegeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss